newsfilter
← Latest News
Business Wire·

Appili Therapeutics Presents at the 10th International Tularemia Conference

Recently announced Funding Commitment from U.S. Air Force is expected to advance ATI-1701 Biodefense Vaccine Candidate to IND Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the "Company" or "Appili"), a